- Home
- FTI vs ILMN Comparison
FTI vs ILMN Comparison
Compare FTI & ILMN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | FTI | ILMN |
|---|---|---|
| Founded | 1884 | 1998 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Metal Fabrications | Medical Specialities |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 16.6B | 18.9B |
| IPO Year | N/A | 2000 |
Fundamental Metrics
Financial Performance| Metric | FTI | ILMN |
|---|---|---|
| Price | $45.28 | $127.28 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 11 | 15 |
| Target Price | $45.60 | ★ $114.93 |
| AVG Volume (30 Days) | ★ 2.6M | 1.5M |
| Earning Date | 10-23-2025 | 10-30-2025 |
| Dividend Yield | ★ 0.44% | N/A |
| EPS Growth | ★ 59.09 | N/A |
| EPS | 2.28 | ★ 4.46 |
| Revenue | ★ $9,803,000,000.00 | $4,288,000,000.00 |
| Revenue This Year | $10.34 | N/A |
| Revenue Next Year | $7.23 | $2.08 |
| P/E Ratio | ★ $19.87 | $28.53 |
| Revenue Growth | ★ 11.44 | N/A |
| 52 Week Low | $22.12 | $68.70 |
| 52 Week High | $47.33 | $153.06 |
Technical Indicators
Market Signals| Indicator | FTI | ILMN |
|---|---|---|
| Relative Strength Index (RSI) | 59.59 | 62.74 |
| Support Level | $44.93 | $124.27 |
| Resistance Level | $47.33 | $129.72 |
| Average True Range (ATR) | 1.15 | 3.80 |
| MACD | -0.05 | -0.58 |
| Stochastic Oscillator | 56.26 | 67.68 |
Price Performance
Historical ComparisonAbout FTI TechnipFMC plc
TechnipFMC is the largest provider of offshore oilfield services, offering integrated deep-water offshore oil and gas development solutions that span the full spectrum of subsea equipment and subsea construction services. The company also provides various pieces of surface equipment used with onshore oil and gas wells. TechnipFMC originated with the 2017 merger of Technip and FMC Technologies.
About ILMN Illumina Inc.
Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates over 90% of its revenue from sequencing instruments, consumables, and services. Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (9% of 2024 sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications.